

Important Update DCH Decision Document

**Listed below are Preferred Drug List changes for the State of Georgia
Fee-For-Service Medicaid and PeachCare for Kids Programs**

EFFECTIVE July 1, 2017 (see chart below)

DCH rebate vendor Change Healthcare (CHC) has reviewed SFY2018 supplemental rebate offers with DCH and also reviewed specific drug categories at the May 2017 DURB meeting. The PDL/PIDL decisions or PDL/PIDL changes for new drugs or categories reviewed during the May DURB meeting are outlined below. **Those drugs highlighted in red indicate a change from current PDL status.** For a full listing of our PDL, go to www.dch.georgia.gov/pharmacy and select the “preferred product list” option.

ONLY DRUGS with Supplemental Rebate Offer or reviewed during the March DURB as either new to market or a change in PDL status are listed	PREFERRED AGENTS	NON-PREFERRED AGENTS
AMINOGLYCOSIDES FOR CYSTIC FIBROSIS		
	BETHKIS	
	KITABIS	
ANAPHYLAXIS EPINEPHRINE PENS		
		EPIPEN, JR
		EPIPEN 2-PAK
ANDROGENS-ANABOLIC		
	ANDROGEL	
ANTICOAGULANTS		
	ELIQUIS	LOVENOX
	PRADAXA	
	XARELTO	
ANTICONVULSANTS		
	LYRICA CAPS	APTIOM
	OXTELLAR XR	FYCOMPA TAB, SUS
	VIMPAT	LYRICA SOLN
		TROKENDI XR
ANTIDEMENTIA AGENTS		
	EXELON	
ANTIDEPRESSANTS		
		FETZIMA
		VIIBRYD
ANTIDIABETICS – INSULIN		
	HUMALOG KWIKPEN U-100	HUMULIN 70/30 KWIKPEN
	HUMALOG MIX 50/50 KWIKPEN	HUMULIN 70-30
	HUMALOG MIX 75/25 KWIKPEN	HUMULIN N
	HUMALOG KWIKPEN U-200	HUMULIN R

ONLY DRUGS with Supplemental Rebate Offer or reviewed during the March DURB as either new to market or a change in PDL status are listed	PREFERRED AGENTS	NON-PREFERRED AGENTS
	HUMULIN R U-500 KWIKPEN	HUMULIN N KWIKPEN
	LANTUS	
	LEVIMIR	
ANTIDIABETICS - NON-INSULIN DPP-IV		
	JANUMET	
	JANUVIA	JANUMET XR
ANTIDIABETICS NON - INSULIN- GLP-1RA		
	BYETTA	TRULICITY
	BYDUREON	
	VICTOZA	
ANTIDIABETICS - NON-INSULIN SGLT2		
		FARXIGA
		GLYXAMBI
		INVOKAMET , XR
		INVOKANA
		JARDIANCE
		SYNJARDY , XR
		XIGDUO XR
ANTIEMETICS		
	DICLEGIS	
ANTIHEMOPHILIC Factor VIII PRODUCTS		
	KOGENATE FS	ADVATE
	XYNTHA	HELIXATE FS
		NUWIQ
		NOVOEIGHT
		KOVALTRY
		ELOCTATE
ANTIHEMOPHILIC Factor IX PRODUCTS		
	BENEFIX	ALPROLIX
ANTHYPERLIPIDEMICS, PCSK9I		
		REPATHA
ANTIPSYCHOTICS, ORAL ATYPICALS		
	LATUDA	SAPHRIS
	REXULTI	VRAYLAR
ANTIPSYCHOTICS, LAI		
	ABILIFY MAINTENA	
	ARISTADA	
	INVEGA SUSTENNA	
	INVEGA TRINZA	
ANTIVIRALS, ANTIRETROVIRALS		
	DESCOVY	LOPINAVIR-RITONAVIR SOLN
	EVOTAZ	ODEFSEY
	GENVOYA	
	NORVIR	
	PREZCOBIX	
ANTIVIRALS, HEPATITIS C DAAS		
	EPCLUSA	DAKLINZA
	HARVONI	
	TECHNIVIE	

ONLY DRUGS with Supplemental Rebate Offer or reviewed during the March DURB as either new to market or a change in PDL status are listed	PREFERRED AGENTS	NON-PREFERRED AGENTS
	VIEKIRA PAK, XR	
	ZEPATIER	
	SOVALDI	
ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)		
	FOCALIN	ADDERALL XR
	FOCALIN XR	ADZENYS XR ODT
	QUILLICHEW ER	APTENSIO XR
	QUILLIVANT XR SUS	DYNAVEL XR SUSP
	VYVANSE	EVEKEO
	ZENZEDI	(effective 09.01.2017) METHYLPHENIDATE ER CPBP 50-50
		(effective 09.01.2017) METHYLPHENIDATE ER TAB
BIOLOGIC IMMUNOMODULATORS		
	ENBREL	XELJANZ, XR
	HUMIRA	
	COSENTYX	
BRONCHODIL, ANTICHOLINERGICS		
	COMBIVENT	ANORO ELLIPTA
		INCRUSE ELLIPTA
		SPIRIVA
		STIOLTO
BRONCHODIL, STEROID INHALANTS		
		ARNUIITY ELPT INH
BRONCHODILATOR SYMPATHOMIMETICS		
		ARCAPTA
		BREO ELLIPTA INH
		STRIVERDI
CV-ANGIOTENSIN MODULATOR/NEPRILYSIN INHIBITOR		
	ENTRESTO	
DERM, ANTI-INFLAMMATORY AGENTS		
		FLECTOR
DERM, SCABICIDES,PEDICULOCIDES		
	NATROBA	
	SKLICE	
GI- DIGESTIVE ENZYMES		
	CREON	PERTZYE
		ZENPEP
GI- INFLAMMATORY BOWEL AGENTS		
	APRISO	
	LIALDA	
	PENTASA	
GI- CONSTIPATION – IBS/OIC		
		LINZESS
		MOVANTIK
GI -IRRITABLE BOWEL SYNDROME -D		
		VIBERZI
GI- LAXATIVES		

ONLY DRUGS with Supplemental Rebate Offer or reviewed during the March DURB as either new to market or a change in PDL status are listed	PREFERRED AGENTS	NON-PREFERRED AGENTS
	PREPOPIK	
GROWTH HORMONE RELEASING HORMONE		
	EGRIFTA	
GROWTH HORMONE		
	GENOTROPIN	
	NORDITROPIN FLEXPRO	
	NUTROPIN AQ	
HEMATAPOIETIC GROWTH FACTOR		
		ARANESP
HEMATAPOIETIC GROWTH FACTOR -CSF		
	GRANIX	
	NEUPOGEN	
HEMATAPOIETIC MIXTURES		
	FUSION PAK SPRINKLE	TANDEM PLUS CAP
	FUSION PLUS CAP	
	HEMOCYTE PLS CAP	
	HEMOCYTE-F TAB	
	INTEGRA F CAP	
	INTEGRA PLUS CAP	
MIGRAINE PRODUCTS		
	RELPAK	
MS AGENTS		
	AUBAGIO	COPAXONE 40 MG/ML SYRINGE
	BETASERON	PLEGRIDY
	GILENYA	
	REBIF	
	TECFIDERA	
MULTIVITAMINS, PRENATAL DHA		
	CONCEPT DHA	
OPHTHALMICS, ADRENERGIC AGENTS		
	SIMBRINZA	
OPHTHALMICS ANTIALLERGICS		
	PAZEO	PATADAY
OPHTHALMIC ANTIBIOTICS - QUINOLONES		
	MOXEZA	OFLOXACIN
	VIGAMOX	ZYMAXID
OPHTHALMIC IMMUNOMODULATORS		
	RESTASIS	XIIDRA
OPHTHALMIC NSAIDS		
	ILEVRO	
OPHTHALMICS STEROID ANTIBIOTIC COMBINATIONS		
	TOBRADEX SUS	
OPHTHALMIC STEROIDS		
	DUREZOL	
OPHTHALMIC STEROIDS INTRAOCULAR		
	ILUVIEN	
OPIOID ABUSE ANALGESICS		
	SUBOXONE	BUNAVAIL

ONLY DRUGS with Supplemental Rebate Offer or reviewed during the March DURB as either new to market or a change in PDL status are listed	PREFERRED AGENTS	NON-PREFERRED AGENTS
		ZUBSOLV
OPIOID LONG ACTING ANALGESICS		
	EMBEDA	HYSINGLA ER
OPIOID-NSAID COMBINATIONS		
	IBUDONE	
OTIC ANTI-INFECTIVES		
	CIPRODEX	OTOVEL
	CIPROFLOXACIN	OFLOXACIN
PHOSPHATE BINDER AGENTS		
	RENAGEL	FOSRENOL
PLATELET AGGREGATION INHIBITORS		
	BRILINTA	
PROGESTINS		
	MAKENA	
PULMONARY HYPERTENSION DRUGS		
	LETAIRIS	OPSUMIT
	TRACLEER	ORENITRAM
SMOKING DETERRENENTS		
		CHANTIX
SPINAL MUSCULAR ATROPHY		
	SPINRAZA	
URINARY ANTISPASMODICS		
	TOVIAZ	MYRBETRIQ
VAGINAL ANTI-INFECTIVES		
	GYNAZOLE-1 CRE	